Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Allergic Disorders
Ligelizumab Gets Breakthrough Tx Status for Chronic Spontaneous Urticaria
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies
Pfizer COVID-19 vaccine should not be administered to individuals with a known history of severe reaction to polyethylene glycol
Orladeyo Now Available for Hereditary Angioedema
The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.
Novel Budesonide Oral Suspension Gets Priority Review for Eosinophilic Esophagitis
The FDA has accepted for review the NDA and granted Priority Review to TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.
FDA Approves Orladeyo to Prevent Hereditary Angioedema Attacks
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
Hormonal Contraceptives Linked to Decline in Asthma Exacerbation
Risk reduced with previous and current use of any and combined hormonal contraceptives, not with progestogen-only use
Crisaborole Safe, Efficacious in Atopic Dermatitis, With or Without Allergic Rhinitis
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Flare Size in Skin Prick Test May Predict Oral Food Challenge Outcomes
Larger skin flare results in pediatric patients correlated to failing certain oral food challenges, but were not predictive of requiring epinephrine.
Dupilumab Demonstrates Long-Term Efficacy, Safety for Improving Asthma Control
Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks
